Baker Tilly Wealth Management LLC Buys 1,399 Shares of Becton, Dickinson and Company $BDX

Key Points

• Baker Tilly Wealth Management LLC increased its stake in Becton, Dickinson and Company by 25.4%, owning a total of 6,898 shares valued at approximately $1.188 million.
• Several analysts have raised their price targets for Becton, Dickinson and Company, with the consensus rating currently at "Hold" and an average target price of $213.30.
• Becton, Dickinson and Company declared a quarterly dividend of $1.04 per share, representing a 2.2% yield, with a payout ratio of 74.82%.

Baker Tilly Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 25.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,898 shares of the medical instruments supplier's stock after purchasing an additional 1,399 shares during the quarter. Baker Tilly Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $1,188,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BDX. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares in the last quarter. FORA Capital LLC purchased a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $3,458,000. Foster Victor Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the 1st quarter valued at $6,406,000. Finally, GAMMA Investing LLC raised its holdings in shares of Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.5%

NYSE:BDX traded down $0.92 during trading hours on Monday, reaching $186.12. The company's stock had a trading volume of 431,196 shares, compared to its average volume of 2,535,151. The firm has a 50-day simple moving average of $187.65 and a 200-day simple moving average of $189.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market capitalization of $53.35 billion, a price-to-earnings ratio of 33.48, a PEG ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the business earned $3.50 earnings per share. The company's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Analysts Set New Price Targets

Several research firms have commented on BDX. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Barclays decreased their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $213.30.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 over the last quarter. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.